“ We want to monetise our societal impact , so that we can make investment decisions based with equal weight , both on social return and financial return ”
— Harald Nusser ,
Head of Novartis Social Business
37
“ It ’ s not only about substance , but whether it will remain stable . Oftentimes children are almost a different species in relation to drug development . It requires us to have a more thoughtful evaluation of what they really need and require , particularly in countries where we are responsible ”. Through a recent , non-financial collaboration with the Global Antibiotic Research & Development Partnership ( GARDP ), NSB has worked to develop a dispersible tablet formulation of what is the most impa-
www . healthcareglobal . com